Sergi Beneyto-Calabuig

Sergi Beneyto-Calabuig

Auto-generated profile, based on publicly available information

Sergi Beneyto-Calabuig

Computational Biology and Health Genomics, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2025 in Nature
Verified
Journal Article
Open access
PDF file
MSMichael Scherer
Michael Scherer
ISIndranil Singh
Indranil Singh
MBMartina Maria Braun
Martina Maria Braun
CSChelsea Szu-Tu
Chelsea Szu-Tu
PSPedro Sanchez Sanchez
Pedro Sanchez Sanchez
LVLars Velten
Lars Velten
Current approaches used to track stem cell clones through differentiation require genetic engineering1,2 or rely on sparse somatic DNA variants3,4, which limits their wide application. Here we discover that DNA methylation of a subset of CpG sites reflects cellular differentiation, whereas another subset undergoes stochastic epimutations and can serve as digital barcodes of clonal identity. We demonstrate that targeted single-cell profiling of DNA methylation5 at single-CpG resolution can accurately extract both layers of information. To that end, we develop EPI-Clone, a method for transgene-free lineage tracing at scale. Applied to mouse and human haematopoiesis, we capture hundreds of clonal differentiation trajectories across tens of individuals and 230,358 single cells. In mouse ageing, we demonstrate that myeloid bias and low output of old haematopoietic stem cells6 are restricted to a small number of expanded clones, whereas many functionally young-like clones persist in old age. In human ageing, clones with and without known driver mutations of clonal haematopoieis7 are part of a spectrum of age-related clonal expansions that display similar lineage biases. EPI-Clone enables accurate and transgene-free single-cell lineage tracing on hematopoietic cell state landscapes at scale.

1 November 2020 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
LCLuke Carroll
Luke Carroll
SJShuwen Jiang
Shuwen Jiang
JIJohanna Irnstorfer
Johanna Irnstorfer
SBSergi Beneyto
Sergi Beneyto
MIMarta T. Ignasiak
Marta T. Ignasiak
Michael DaviesMichael Davies
Michael Davies

3 April 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
STSumiko Takao
Sumiko Takao
VMVictor Morell
Victor Morell
MUMasahiro Uni
Masahiro Uni
ASAlicia Slavit
Alicia Slavit
SRSophia Rha
Sophia Rha
AKAlex Kentsis
Alex Kentsis
Cancer stem cells are essential for initiation and therapy resistance of many cancers, including acute myeloid leukemias (AML). Here, we apply functional genomic profiling to diverse human leukemias, including high-risk MLL- and NUP98-rearranged specimens, using label tracing in vivo. Human leukemia propagation is mediated by a rare quiescent label-retaining cell (LRC) population undetectable by current immunophenotypic markers. AML quiescence is reversible, preserving genetic clonal competition and epigenetic inheritance. LRC quiescence is defined by distinct promoter-centered chromatin and gene expression dynamics controlled by an AP-1/ETS transcription factor network, where JUN is necessary and sufficient for LRC quiescence and associated with persistence and chemotherapy resistance in diverse patients. This enables prospective isolation and manipulation of immunophenotypically-varied leukemia stem cells, establishing the functions of epigenetic plasticity in leukemia development and therapy resistance. These findings offer insights into leukemia stem cell quiescence and the design of therapeutic strategies for their clinical identification and control.

1 April 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
MSMichael Scherer
Michael Scherer
ISIndranil Singh
Indranil Singh
MBMartina Braun
Martina Braun
CSChelsea Szu-Tu
Chelsea Szu-Tu
MKMichael Kardorff
Michael Kardorff
LVLars Velten
Lars Velten
Summary: Current approaches to lineage tracing of stem cell clones require genetic engineering or rely on sparse somatic DNA variants, which are difficult to capture at single-cell resolution. Here, we show that targeted single-cell measurements of DNA methylation at single-CpG resolution deliver joint information about cellular differentiation state and clonal identities. We develop EPI-clone, a droplet-based method for transgene-free lineage tracing, and apply it to study hematopoiesis, capturing hundreds of clonal trajectories across almost 100,000 single-cells. Using ground-truth genetic barcodes, we demonstrate that EPI-clone accurately identifies clonal lineages throughout hematopoietic differentiation. Applied to unperturbed hematopoiesis, we describe an overall decline of clonal complexity during murine ageing and the expansion of rare low-output stem cell clones. In aged human donors, we identified expanded hematopoietic clones with and without genetic lesions, and various degrees of clonal complexity. Taken together, EPI-clone enables accurate and transgene-free single-cell lineage tracing at scale.

29 August 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
SBSergi Beneyto-Calabuig
Sergi Beneyto-Calabuig
ALAnne Kathrin Ludwig
Anne Kathrin Ludwig
JKJonas-Alexander Kniffka
Jonas-Alexander Kniffka
CSChelsea Szu-Tu
Chelsea Szu-Tu
CRChristian Rohde
Christian Rohde
LVLars Velten
Lars Velten
Inter-patient variability and the similarity of healthy and leukemic stem cells have impeded the characterization of leukemic stem cells (LSCs) in acute myeloid leukemia (AML), and their differentiation landscape. Here, we introduce CloneTracer, a novel method that adds clonal resolution to single-cell RNA-seq datasets. Applied to samples from 19 AML patients, CloneTracer revealed routes of leukemic differentiation. While residual healthy cells dominated the dormant stem cell compartment, active leukemic stem cells resembled their healthy counterpart and retained erythroid capacity. By contrast, downstream myeloid progenitors were highly aberrant and constituted the disease-defining compartment: Their gene expression and differentiation state determined both chemotherapy response and the leukemia’s ability to differentiate to transcriptomically normal monocytes. Finally, we demonstrated the potential of CloneTracer to identify surface markers mis-regulated specifically in leukemic cells by intra-patient comparisons. Taken together, CloneTracer revealed a differentiation landscape that mimics its healthy counterpart and determines biology and therapy response in AML.